Week in Review: Charles River Labs Buys China’s Vital River
Charles River Labs will pay $27 million to acquire a 75% stake in Vital River, the largest supplier of laboratory animals in China; Fosun Pharma posted a loss in its first day of trading in Hong Kong; DelMar Pharma of Canada and Guangxi Wuzhou Pharma will expand their collaboration by seeking approval of new indications of Wuzhou’s cancer drug in China; Hutchison MediPharma began a Phase I clinical trial of Theliatinib in patients with lung cancer; a new generic GI drug from Sihuan Pharma received SFDA approval; SLG-Giant Pharm Service Group, a China clinical-stage CRO, will conduct the China arm of a hypertension trial for the NIH of the US; Innovent Biologics of Suzhou, which intends to in-license biologic drugs and provide CMO services, is building a biotech manufacturing facility in BioBay; and Xiamen Innovax Biotech has launched Hecolin, the world's first hepatitis E vaccine, in the China market. More details…. Stock Symbols: (NYSE: CRL) (SHA: 600196; HK: 2196) (AIM: HCM) (HK: 0460) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here